Tibial Metastasis from Muscle Invasive Bladder Carcinoma: An Unusual Site

David Brennan       Michael E. Kelly       Gregory J. Nason
Coilin Collins-Smyth       Barry B. McGuire       Gerald M. Lennon
Department of Urology, St Vincent’s University Hospital, Elm Park, Dublin, Ireland

Case Report

A 61-year-old gentleman and a current smoker with a background history of hypertension and current smoker (45 pack/year history) presented with 3-week history of painless frank hematuria with associated weight loss (10 kg). Initial ultrasound revealed hydronephrosis of the left kidney with chronic cortical thinning. Creatinine at presentation was 110 µmol/l. Cystoscopy revealed an irregular raised lesion at the left ureteric junction. He proceeded to have a transurethral resection of the bladder tumor. Histology confirmed a poorly differentiated urothelial carcinoma with prominent squamous differentiation. The tumor infiltrated muscle extensively (pT2G3). Computerised tomography (CT) scan of thorax/abdomen/pelvis demonstrated a distal ureteric mass extending to left vesico-ureteric junction with severe left hydronephrosis. No other sign of metastasis was noted.

The patient also reported a 6-week history of left knee pain, requiring regular analgesia, disrupting his sleep and restricting daily activities. Plain film radiographs of the knee showed a 3.4 cm subtle lytic lesion involving the medial portion the left tibia (fig. 1). Radionuclide whole body bone scan demonstrated intense uptake at this point, with no other bony infiltration. Magnetic resonance imaging (MRI) displayed a 4.1 cm lesion with extensive marrow edema, consistent with metastasis (fig. 2). A bone biopsy of this lesion confirmed high grade carcinoma with papillary morphology and squamous differentiation, consistent with metastatic urothelial carcinoma.
Following discussion at the multi disciplinary meeting, he underwent a left total knee replacement and was commenced on a course of chemotherapy (cisplatin and gemcitabine). On review in the clinic at 2 months, he is mobile and pain free. He is undergoing regular surveillance cystoscopy.

Discussion

Transitional cell carcinoma (TCC) represents the vast majority of malignant bladder tumors. The most frequent site of metastases of TCC is to lymph nodes (51–88%), lung (36–40%), bone (22–37%) and adrenal glands (6–21%) [2]. Data suggests that bone metastasis represent a surrogate to the degree of muscle invasion of the bladder neoplasm [2]. About 30% of patients at presentation have muscle invasive disease, with 10–15% having metastatic disease evident [3]. Another 30% of newly diagnosed bladder neoplasms are likely to have occult metastatic disease [3].

The spine and pelvis are the most common bony metastatic deposit sites. Hematogenous seeding is the most common source for bladder neoplasm metastasis [4]. It has been postulated that the propensity for bladder and other urological malignancies to disseminate to the spine is due to the anatomical relationship between the urological venous system and the large network of vertebral veins known as Batson’s plexus [5].

Typical presentation of bone metastasis includes extensive bone pain with subsequent loss of function. Imaging is integral in assessing risk of pathological fracture. Conventional imaging has been largely replaced with higher imaging modality including CT or MRI scans. Isotope bone scan, though frequently used due to high sensitivity, lacks the specificity of CT or MRI [6]. Bone biopsy is often a viable option (under CT guidance) if there is any discrepancy in diagnosis or results changing management strategy [6].

The presence of bony involvement in bladder neoplasm indicates an advanced disease process. Median survival of between 6 and 12 months has been reported with bone metastasis [7]. Management of bony metastasis includes pain control with analgesia and/or radiotherapy. Orthopedic consultation is crucial for pre-emptive surgical management to stabilize and maintain functional status. Mirel’s score highlights those that would benefit from prophylactic fixation of long bones with metastatic...
lesions. This score is based on the lesion site, size, pain severity and nature (lytic, sclerotic or mixed) [8]. Prophylactic fixation has been associated with significant symptom relief. Our case represents an unusual location of bone metastasis from TCC of the bladder, to the best of our knowledge this is the first reported case of a tibial metastasis.

Conclusion

Muscle-invasive bladder cancer carries a substantial risk of bone metastasis. This should be suspected in all patients presenting with bone pain and/or loss of function. Clinicians should be aware of atypical presentations of bone metastasis, as well as the importance of early orthopedic review in management of these patients.

References